Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cibinetide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.49 |
| ▸ | EP300 | Q09472 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.47 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | APLNR | P35414 | 3/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.42 |
| ▸ | GNRHR | P30968 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cibinetide SCHEMBL29367092 | 0.88 | TFPI (0.45) | NMUR2 | |
| SCHEMBL29727699 | 0.80 | OPRL1 (0.43) | APLNRHCRTR1HCRTR2 | |
| SCHEMBL30729466 | 0.76 | NPY1R (0.59) | — | |
| SCHEMBL7787541 | 0.76 | HDAC3 (0.40) | OPRK1NMUR2F2 | |
| SCHEMBL7787536 | 0.76 | HDAC3 (0.40) | OPRK1NMUR2F2 | |
| Nonathymulin SCHEMBL2109423 | 0.76 | OPRL1 (0.42) | APLNRHCRTR1HCRTR2 | |
| Nonathymulin SCHEMBL29727660 | 0.76 | OPRL1 (0.42) | APLNRHCRTR1HCRTR2 | |
| SCHEMBL29416863 | 0.75 | OPRK1 (0.46) | OPRK1 | |
| SCHEMBL29713552 | 0.75 | OPRK1 (0.46) | OPRK1 | |
| SCHEMBL11579956 | 0.75 | KDM1A (0.42) | OPRK1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263435-A1 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | Lateral IP Pty Ltd (AU) | 2025-08-21 | — | — | US | claimed |
| US-20250002534-A1 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | Lateral IP Pty Ltd (AU) | 2025-01-02 | — | — | US | claimed |
| CN-119033913-A | Application of EPO-derived peptide in preparation of medicines for treating pulmonary fibrosis | 中国人民解放军陆军军医大学 | 2024-11-29 | — | — | CN | claimed |
| EP-3720468-B1 | TISSUE REPAIR | UNIV SUSSEX (GB) | 2024-10-30 | — | — | EP | claimed |
| EP-4373509-A1 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | LATERAL IP PTY LTD (AU) | 2024-05-29 | — | — | EP | claimed |
| CN-117813105-A | Peptide compositions capable of binding lanthionine synthase C-like protein (LANCL) and uses thereof | 横向知识产权私人有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-3538065-B1 | COSMETIC FORMULATIONS FOR TOPICAL APPLICATIONS CONTAINING ERYTHROPOIETIN-DERIVED MOLECULES | ASC REGENITY LTD (GB) | 2023-08-02 | — | — | EP | claimed |
| US-11596668-B2 | Tissue repair | THE UNIVERSITY OF SUSSEX (GB) | 2023-03-07 | — | — | US | claimed |
| WO-2023000038-A1 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | Lateral IP Pty Ltd (AU) | 2023-01-26 | — | — | WO | claimed |
| CN-110234311-B | Cosmetic preparation for topical application containing erythropoietin-derived molecules | ASC瑞珍尼特有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-20220186256-A1 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | REGENXBIO INC. | 2022-06-16 | — | — | US | claimed |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | IMMUNEDGE, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | IMMUNEDGE INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12540189-B2 | — | — | 2026-02-03 | — | — | US | disclosed |
| US-12492223-B2 | Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof | Lateral IP Pty Ltd (AU) | 2025-12-09 | — | — | US | disclosed |
| WO-2023000038-A1 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | Lateral IP Pty Ltd (AU) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022272026-A1 | METHODS AND COMPOSITIONS RELATING TO TISSUE-PROTECTIVE ERYTHROPOIETIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-110234311-B | Cosmetic preparation for topical application containing erythropoietin-derived molecules | ASC瑞珍尼特有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20220186256-A1 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | REGENXBIO INC. | 2022-06-16 | — | — | US | disclosed |
| CN-114127089-A | Recombinant adeno-associated virus and use thereof | 再生生物股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220186256-A1 | RECOMBINANT ADENO-ASSOCIATED VIRUSES AND USES THEREOF | EPOR, DNAH12, ATP6V1B2 | OPRK1 1570/4885EP300 3734/4885GRIN2D 2091/4885 |
| US-20250002534-A1 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | LANCL2, ARGLU1, GLUL | OPRK1 4777/4885EP300 4360/4885GRIN2D 2468/4885 |
| US-12492223-B2 | Peptide compositions capable of binding lanthionine synthetase C-like protein (LanCl) and uses thereof | LANCL2, ARGLU1, GLUL | OPRK1 4777/4885EP300 4360/4885GRIN2D 2468/4885 |
| US-20250263435-A1 | PEPTIDE COMPOSITIONS CAPABLE OF BINDING LANTHIONINE SYNTHETASE C-LIKE PROTEIN (LANCL) AND USES THEREOF | LANCL2, LANCL1, QPCTL | OPRK1 3352/4885EP300 4389/4885GRIN2D 3388/4885 |
| US-12540189-B2 | — | EPOR, MPL, JAK2 | OPRK1 2320/4885EP300 2240/4885GRIN2D 3476/4885 |
| US-12637513-B2 | Method of treating cancer by administering an inhibitor of erythropoietin receptor activity comprising either erythropoietin receptor or erythropoietin protein | EPOR, MPL, CSF3R | OPRK1 1839/4885EP300 2145/4885GRIN2D 3635/4885 |
| US-20260116986-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, STAT5A, JAK2 | OPRK1 574/4885EP300 2872/4885GRIN2D 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.